Since 2008 Recce Pharmaceuticals has expanded to include a diverse management team of experts in clinical research and business development who are committed to addressing the urgent global health threat posed by antibiotic resistance.
Former Executive Director and Head of Research at Johnson & Johnson (Aus) in Sydney, with global responsibilities, particularly in Asia-Pacific.
US based, current Chairman and Co-founder of Palatin Technologies, Inc. (NYSE: PTN) and Lead Director of Heat Biologics, Inc. (NASDAQ: HTBX) – extensive experience in the international commercialisation of pharmaceutical technologies.
Co-inventor and qualified medical scientist; specialisation in medical microbiology and regulatory affairs.
Extensive experience in marketing, business development and commercialisation of early stage technologies with global potential.
A quality control expert who has worked with leading pharmaceutical companies according to international regulatory standards.
US based, Director of Cytogel Pharma LLC, Palatin Technologies and Oragenics Inc. Over 30 years of senior pharmaceutical experience, leading clinical research development and advancing drug candidates through regulatory review and commercialisation.
Highly qualified in chemical engineering and microbiology, has significant experience taking a new technology concept to pilot plant and full-scale to FDA standards and production internationally.
Experienced marketing specialist in the pharmaceutical and clinical trial sector; specialisation in digital marketing campaigns and targeting key investors in the healthcare industry.
Alistair is a qualified lawyer and Principal of Automic Legal. Alistair has broad experience as a commercial litigator and Company Secretary to ASX Listed companies.
Justin is a qualified accountant and Partner of Pitcher Partners Sydney. Justin has broad experience covering all areas of accounting, taxation and assurance. Particularly, Justin’s areas of expertise are business services and outsourced accounting.
Receive news and information direct to your inbox.
ASX: